A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment persistence, loss of response, or adverse events in patients with inflammatory ...
The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...
Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.
Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics ...
Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face ...
Number 3: Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is ...
In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...
The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory ...
A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford ...
The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion ...
The Inflation Reduction Act (IRA) has modestly boosted oncology biosimilar uptake through Medicare reimbursement, but its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback